Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HCWBNASDAQ:KANASDAQ:MEIPNASDAQ:NRXP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHCWBHCW Biologics$4.67+2.2%$7.09$4.50▼$100.80$6.58M0.83262,928 shs59,629 shsKAKineta$0.66$0.33▼$5.39$7.04M0.46409,478 shs530,700 shsMEIPMEI Pharma$2.20$2.13$1.46▼$4.10N/A0.1643,206 shs4,735 shsNRXPNRx Pharmaceuticals$3.10-4.9%$2.55$1.10▼$6.01$56.36M1.54413,660 shs318,957 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHCWBHCW Biologics+2.19%-12.71%-44.21%-61.16%-83.85%KAKineta0.00%0.00%0.00%0.00%-10.91%MEIPMEI Pharma0.00%-1.35%+2.09%-6.38%-23.08%NRXPNRx Pharmaceuticals-4.91%-10.92%+18.32%+54.23%+16.98%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHCWBHCW Biologics2.716 of 5 stars3.55.00.00.00.03.30.0KAKinetaN/AN/AN/AN/AN/AN/AN/AN/AMEIPMEI Pharma1.5682 of 5 stars0.03.00.04.10.00.81.3NRXPNRx Pharmaceuticals1.9675 of 5 stars3.61.00.00.02.50.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHCWBHCW Biologics 3.00Buy$35.00649.46% UpsideKAKineta 0.00N/AN/AN/AMEIPMEI Pharma 2.00HoldN/AN/ANRXPNRx Pharmaceuticals 3.20Buy$28.50819.35% UpsideCurrent Analyst Ratings BreakdownLatest NRXP, KA, HCWB, and MEIP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/20/2025NRXPNRx PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.006/6/2025NRXPNRx PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.005/29/2025HCWBHCW BiologicsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$120.00 ➝ $35.005/16/2025NRXPNRx PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.00 ➝ $31.004/30/2025NRXPNRx PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.00 ➝ $31.004/29/2025NRXPNRx PharmaceuticalsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$45.00 ➝ $46.004/2/2025NRXPNRx PharmaceuticalsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$18.003/31/2025NRXPNRx PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.00 ➝ $31.003/24/2025NRXPNRx PharmaceuticalsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$31.00 ➝ $31.00(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHCWBHCW Biologics$2.57M2.62N/AN/A($6.08) per share-0.77KAKineta$5.44M0.00N/AN/A$0.29 per share0.00MEIPMEI Pharma$65.30MN/A$5.95 per share0.37$4.96 per shareN/ANRXPNRx PharmaceuticalsN/AN/AN/AN/A($1.48) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHCWBHCW Biologics-$30.02M-$23.25N/A∞N/A-1,712.94%-2,516.84%-90.09%8/13/2025 (Estimated)KAKineta-$14.10M-$1.50N/AN/AN/AN/A-1,044.95%-336.46%N/AMEIPMEI Pharma$17.78M-$4.75N/AN/AN/AN/A-77.00%-64.79%N/ANRXPNRx Pharmaceuticals-$25.13M-$2.01N/AN/AN/AN/AN/A-355.00%8/13/2025 (Estimated)Latest NRXP, KA, HCWB, and MEIP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025HCWBHCW BiologicsN/A-$0.05N/A-$0.05N/AN/A5/15/2025Q1 2025NRXPNRx Pharmaceuticals-$0.40-$0.34+$0.06-$0.34$1.14 million$1.14 million5/13/2025Q3 2025MEIPMEI PharmaN/A-$0.39N/A-$0.39N/AN/A3/28/2025Q4 2024HCWBHCW BiologicsN/A-$3.20N/A-$0.08N/A$0.40 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHCWBHCW BiologicsN/AN/AN/AN/AN/AKAKinetaN/AN/AN/AN/AN/AMEIPMEI PharmaN/AN/AN/AN/AN/ANRXPNRx PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHCWBHCW BiologicsN/A0.070.07KAKineta0.050.140.14MEIPMEI PharmaN/A16.7816.78NRXPNRx PharmaceuticalsN/A0.220.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHCWBHCW Biologics2.96%KAKineta30.32%MEIPMEI Pharma52.38%NRXPNRx Pharmaceuticals4.27%Insider OwnershipCompanyInsider OwnershipHCWBHCW Biologics42.70%KAKineta23.70%MEIPMEI Pharma3.12%NRXPNRx Pharmaceuticals19.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHCWBHCW Biologics401.44 million825,000Not OptionableKAKineta4012.25 million9.35 millionNot OptionableMEIPMEI Pharma100N/AN/AOptionableNRXPNRx Pharmaceuticals217.29 million14.00 millionOptionableNRXP, KA, HCWB, and MEIP HeadlinesRecent News About These CompaniesNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Filing of Commissioner's National Priority Voucher Application for Intravenous Ketamine (NRX-100)June 23 at 8:03 AM | prnewswire.comNRx Pharmaceuticals (NASDAQ:NRXP) Receives "Buy" Rating from D. Boral CapitalJune 20, 2025 | marketbeat.comNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives $28.50 Average Price Target from BrokeragesJune 19, 2025 | americanbankingnews.comIBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Forms Investor Relations Partnership With astr PartnersJune 17, 2025 | finance.yahoo.comNRx Pharmaceuticals (NASDAQ: NRXP) Forms Investor Relations Partnership With astr PartnersJune 16, 2025 | financial-news.co.ukNRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and HOPE Therapeutics, Inc. ...June 16, 2025 | gurufocus.comNRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and HOPE Therapeutics, Inc. Announce Strategic Investor Relations Partnership with astr partnersJune 16, 2025 | prnewswire.comNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Average Rating of "Buy" from BrokeragesJune 16, 2025 | marketbeat.comNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics, Inc. to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid ConferenceJune 12, 2025 | prnewswire.comNRx Pharmaceuticals (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic NetworkJune 6, 2025 | financial-news.co.ukIBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic NetworkJune 6, 2025 | finance.yahoo.comNRx Pharmaceuticals' (NRXP) "Buy" Rating Reaffirmed at D. Boral CapitalJune 6, 2025 | marketbeat.comNRx Pharmaceuticals (NASDAQ: NRXP) Files ANDA for Preservative-Free IV KetamineJune 5, 2025 | financial-news.co.ukIBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Files ANDA for Preservative-Free IV KetamineJune 5, 2025 | finance.yahoo.comNew to The Street Signs National Media Agreement with NRx Pharmaceuticals for 12-Part Broadcast Series Across TV, Digital, and Outdoor PlatformsJune 5, 2025 | usatoday.comNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Abbreviated New Drug Application (ANDA) for Preservative-Free IV KetamineJune 5, 2025 | prnewswire.comIBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Announces $10.3M Financing to Expand HOPE Clinic Network, Advances FDA Drug ApprovalMay 29, 2025 | finance.yahoo.comNRx Pharmaceuticals (NASDAQ: NRXP) Announces $10.3M Financing to Expand HOPE Clinic Network, Advances FDA Drug ApprovalMay 28, 2025 | financial-news.co.ukNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Acquires Kadima Institute to Launch $100M Psychiatry Clinic NetworkMay 28, 2025 | msn.comNRx Pharmaceuticals (NASDAQ: NRXP) Subsidiary, HOPE Therapeutics, to Expand Interventional Psychiatry Treatment with Kadima Institute AcquisitionMay 27, 2025 | financial-news.co.ukNRx Pharmaceuticals (NASDAQ: NRXP) to Present at Wall Street Conference on May 21May 23, 2025 | financial-news.co.ukNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeThese 3 Stocks Are Buying Back Billions in SharesBy Leo Miller | June 3, 2025View These 3 Stocks Are Buying Back Billions in SharesIs Consumer Discretionary a Dead End? These 3 Stocks Say NoBy Nathan Reiff | June 11, 2025View Is Consumer Discretionary a Dead End? These 3 Stocks Say NoWall Street Sees More Upside for Dell and HPEBy Leo Miller | June 12, 2025View Wall Street Sees More Upside for Dell and HPENRXP, KA, HCWB, and MEIP Company DescriptionsHCW Biologics NASDAQ:HCWB$4.67 +0.10 (+2.19%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$4.63 -0.04 (-0.86%) As of 06:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.Kineta NASDAQ:KAKineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, renal cell carcinoma, head and neck, renal cell, and colorectal cancers. It is also developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The company has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. is headquartered in Seattle, Washington.MEI Pharma NASDAQ:MEIP$2.20 0.00 (0.00%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$2.20 0.00 (0.00%) As of 06/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.NRx Pharmaceuticals NASDAQ:NRXP$3.10 -0.16 (-4.91%) Closing price 06/23/2025 04:00 PM EasternExtended Trading$3.14 +0.03 (+1.13%) As of 05:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
